Safety of COVID-19 Vaccination in Inflammatory Bowel Disease Patients on Biologic Therapy
Open Access
- 30 October 2021
- journal article
- conference paper
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 16 (4) , 687-688
Abstract
We read with great interest the manuscript by Wellens et al. reviewing the evidence on SARS-CoV-2 vaccination in patients with inflammatory bowel disease [IBD].1 The authors highlight that IBD patients should receive vaccination against SARS-CoV-2. In fact, the International Organization for the Study of IBD has already recommended vaccinating all patients with IBD as soon as they are able to receive the vaccine, regardless of immune-modifying therapies or disease activity.2Keywords
This publication has 6 references indexed in Scilit:
- Inflammatory Bowel Disease and COVID-19 Vaccination: A Patients’ SurveyDigestive Diseases and Sciences, 2021
- SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future ChallengesJournal of Crohn's and Colitis, 2021
- First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021MMWR. Morbidity and Mortality Weekly Report, 2021
- SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meetingGut, 2021
- A global survey of potential acceptance of a COVID-19 vaccineNature Medicine, 2020
- Gynæcologic Symptoms in Patients with Non-cœliac Wheat SensitivityDigestive Diseases and Sciences, 2020